NASDAQ: VCYTVeracyte Inc Stock
$30.60-0.54 (-1.73%)
Updated Apr 21, 2025
VCYT Price
$30.60
Fair Value Price
$0.64
Market Cap
$2.39B
52 Week Low
$19.09
52 Week High
$47.32
P/E
95.63x
P/B
2.03x
P/S
6.8x
PEG
1.47x
Dividend Yield
N/A
Revenue
$445.76M
Earnings
$24.14M
Gross Margin
66.9%
Operating Margin
5.78%
Profit Margin
5.4%
Debt to Equity
0.11
Operating Cash Flow
$75M
Beta
1.93
Next Earnings
May 5, 2025
Ex-Dividend
N/A
Next Dividend
N/A
VCYT Overview
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine VCYT's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
VCYT
Ranked#59 of 462
Ranked#59 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.55 | A | |
| $7.66 | A | |
| $22.02 | A |
Be the first to know about important VCYT news, forecast changes, insider trades & much more!
VCYT News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how VCYT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
VCYT ($30.60) is overvalued by 4,678.98% relative to our estimate of its Fair Value price of $0.64 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
VCYT ($30.60) is not significantly undervalued (4,678.98%) relative to our estimate of its Fair Value price of $0.64 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
VCYT ($30.60) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more VCYT due diligence checks available for Premium users.
Valuation
VCYT fair value
Fair Value of VCYT stock based on Discounted Cash Flow (DCF)
Price
$30.60
Fair Value
$0.64
Overvalued by
4,678.98%
VCYT ($30.60) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
VCYT ($30.60) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
VCYT ($30.60) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
VCYT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
95.63x
Industry
-184.27x
Market
27.14x
VCYT is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
VCYT is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
VCYT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.03x
Industry
4.04x
VCYT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
VCYT price to earnings growth (PEG)
For valuing profitable companies with growth potential
VCYT is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
VCYT's financial health
Profit margin
Revenue
$118.6M
Net Income
$5.1M
Profit Margin
4.3%
VCYT's Earnings (EBIT) of $25.74M... subscribe to Premium to read more.
Interest Coverage Financials
VCYT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.3B
Liabilities
$124.1M
Debt to equity
0.11
VCYT's short-term assets ($372.27M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VCYT's short-term assets ($372.27M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VCYT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
VCYT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$24.5M
Investing
-$54.1M
Financing
-$4.5M
VCYT's operating cash flow ($75.10M)... subscribe to Premium to read more.
Debt Coverage Financials
VCYT vs Biotech Stocks
Veracyte Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.